Allworth Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Allworth Financial’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-509	Closed	-$4.74K	–	5239
2026 Q1	$4.74K	Buy	+509	New	+$4.43K	﹤0.01%	3996
2025 Q4	–	Sell	-393	Closed	-$3.42K	–	5097
2025 Q3	$3.42K	Buy	393 +243	+162%	+$1.45K	﹤0.01%	3751
2025 Q2	$557	Buy	+150	New	+$527	﹤0.01%	4108
2024 Q3	–	Sell	-28	Closed	-$404	–	3773
2024 Q2	$404	Hold	28	–	–	﹤0.01%	3426
2024 Q1	$893	Buy	+28	New	+$714	﹤0.01%	3118

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Allworth Financial's FDMT Position: Q2 2026 in Review

Allworth Financial sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 509 shares — an estimated $4.74K sold.

Allworth Financial first reported a position in FDMT in Q1 2024 and held it in 5 quarters. The position peaked at $4.74K in Q1 2026. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Allworth Financial reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
Allworth Financial sold 509 4D Molecular Therapeutics shares in Q2 2026, an estimated $4.74K.
Allworth Financial first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 5 quarters.
Allworth Financial's 4D Molecular Therapeutics position peaked at $4.74K in Q1 2026.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.